MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
1.710
-0.040
-2.29%
Opening 11:58 12/07 EST
OPEN
1.820
PREV CLOSE
1.750
HIGH
1.850
LOW
1.710
VOLUME
53.81K
TURNOVER
54.02K
52 WEEK HIGH
7.90
52 WEEK LOW
1.710
MARKET CAP
16.05M
P/E (TTM)
-0.3827
1D
5D
1M
3M
1Y
5Y
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announ...
GlobeNewswire · 11/30 13:30
BRIEF-Cellectar Biosciences Files For Resale Of Up To 7.03 Mln Shares Of Common Stock - SEC Filing
Reuters · 11/23 21:24
Cellectar Biosciences Announces Presentation Of Data On CLR 12120 Series Of Targeted Alpha-Emitting Therapies At The 13th Annual World ADC Conference
Benzinga · 11/21 13:43
Cellectar Announces Resolution Of Breach of Contract And Intellectual Property Dispute
Benzinga · 11/16 13:36
--HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating
--HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating
MT Newswires · 11/04 13:11
--Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating
--Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating
MT Newswires · 11/04 10:52
HC Wainwright & Co. Maintains Buy on Cellectar Biosciences, Raises Price Target to $4
Benzinga · 11/04 10:27
Recap: Cellectar Biosciences Q3 Earnings
Benzinga · 11/03 13:25
More
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through Phospholipid Drug Conjugate (PDC) platform, is focused on to develop PDCs that are designed to target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The Company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The Company is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase II CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase II CLOVER-2 study.

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.